8-K: Tilray Brands Achieves Record Q2 Revenue, Shifts to Net Cash

Tilray Brands reported record Q2 fiscal 2026 net revenue of $218 million, moved to a net cash position, and reaffirmed its full-year Adjusted EBITDA guidance.

Summary

• Tilray Brands achieved record Q2 fiscal 2026 net revenue of $217.5 million, marking a 3% increase compared to the prior year period.
• The company transitioned from a net debt position of $3.8 million in Q1 to an overall net cash position of $27.4 million in Q2, a sequential improvement of $31.2 million.
• Full-year Adjusted EBITDA guidance for fiscal 2026 was reaffirmed at $62 million to $72 million.
• International medical cannabis revenue increased by 36%, and Canadian adult-use cannabis revenue grew by 6%.
• The Distribution business, including Tilray Pharma, recorded its highest quarterly revenue ever at $85.3 million, up from $67.6 million in the prior year.
• Net loss improved significantly by $41.8 million to $(43.5) million, compared to a net loss of $(85.3) million in the prior year.
• Adjusted net loss improved to $(2.0) million from $(2.2) million, and excluding non-cash income tax charges, adjusted net income was $1.6 million.
• Cash used in operations improved by $32.2 million to $(8.5) million.
• The balance of cash and marketable securities grew to $291.6 million, and total outstanding debt was reduced by $4.2 million.

Sentiment

Score: 7

Explanation: The company reported record net revenue and a significant improvement in its financial position by moving to a net cash position. While some segments like beverages saw declines, growth in international cannabis and distribution, coupled with reaffirmed guidance and strategic positioning for U.S. cannabis rescheduling, indicates a generally positive outlook and disciplined execution.

Positives

• Record Q2 fiscal 2026 net revenue of $217.5 million, representing a 3% year-over-year increase.
• Achieved a net cash position of $27.4 million, a substantial $31.2 million sequential improvement from the prior quarter's net debt position.
• Maintained a strong balance sheet with $291.6 million in cash and marketable securities.
• Net loss improved significantly by $41.8 million to $(43.5) million, and adjusted net loss improved to $(2.0) million.
• Excluding non-cash income tax charges, the company reported an adjusted net income of $1.6 million.
• International medical cannabis revenue surged by 36%, indicating strong global market penetration.
• Canadian adult-use cannabis revenue increased by 6%.
• The Distribution business, including Tilray Pharma, achieved its highest quarterly revenue ever at $85.3 million, a 26% increase year-over-year.
• Cannabis gross margin improved to 39% from 35%, Wellness gross margin increased to 32% from 31%, and Distribution gross margin increased to 13% from 12%.
• Cash used in operations improved substantially by $32.2 million, reflecting better operational efficiency.
• Total outstanding debt was reduced by $4.2 million, strengthening the balance sheet.
• Reaffirmed full-year Adjusted EBITDA guidance of $62 million $72 million, signaling confidence in future performance.
• Anticipates new market opportunities in the U.S. with expected federal cannabis rescheduling, positioning the company for future growth.

Negatives

• Overall gross profit decreased to $57.5 million from $61.2 million in the prior year period.
• Consolidated gross margin declined to 26% from 29% year-over-year.
• Beverage net revenue decreased by 21% to $50.1 million from $63.1 million.
• Beverage gross profit decreased to $15.7 million from $25.2 million, and beverage gross margin declined to 31% from 40%.
• Adjusted EBITDA slightly decreased to $8.4 million from $9.0 million.
• Experienced a lower presence in Canadian wholesale cannabis in anticipation of deployment in international markets.

Risks

• Actual results, performance, or achievement could be materially different from forward-looking statements due to various factors.
• Other risks and uncertainties not presently known to the Company or deemed immaterial could cause actual results or events to differ materially from those expressed in forward-looking statements.
• The realization of new market opportunities in the U.S. is contingent on the expected federal cannabis rescheduling and the progression of a favorable regulatory landscape.

Future Outlook

Tilray Brands reaffirmed its full-year Adjusted EBITDA guidance of $62 million to $72 million for fiscal 2026. The company anticipates significant new market opportunities in the U.S. with the expected federal cannabis rescheduling, planning to leverage its existing Tilray Medical U.S. platform, its expected $150 million global medical cannabis business, and its $300 million Tilray Pharma medical distribution platform to expand research, initiate new FDA trials, and develop new products. The company aims for sustainable profitability and long-term shareholder value enhancement through operational scale, market share growth, and strategic investments.

Management Comments

• "We achieved another record quarter with net revenue reaching $218 million, a result of disciplined execution within our diversified portfolio spanning cannabis, beverage, wellness and distribution sectors."
• "Our business model supports scalability, adaptability in challenging markets, and long-term value creation, as demonstrated by our ability to perform while reinforcing our core operations."
• "The quarter concluded with a strong balance sheet and ample liquidity, highlighting our prudent financial management and affording us flexibility for selective investment in strategic growth initiatives."
• "As we continue expanding our operations and pursuing our priorities, we remain committed to achieving sustainable profitability and enhancing long-term shareholder value."
• "We believe federal rescheduling would mark an important advancement for medical cannabis in the United States, paving the way for more research, wider physician involvement, and better patient access."
• "Tilray is prepared to leverage its experience to play a key role in building a responsible, research-oriented national medical cannabis industry."

Industry Context

Tilray Brands operates within the dynamic cannabis, beverage, and wellness industries. The company's focus on international medical cannabis growth (36% increase) and anticipation of U.S. federal cannabis rescheduling positions it to capitalize on evolving regulatory landscapes and expanding markets. While the beverage segment faced revenue declines, the record performance of the distribution business, including Tilray Pharma, highlights strength in pharmaceutical distribution, a key area for future medical cannabis expansion. The broader industry is watching U.S. rescheduling closely, as it could significantly alter market access and growth opportunities for established players like Tilray.

Stakeholder Impact

• Shareholders: Potential for enhanced long-term value creation through strategic growth initiatives, improved financial health (net cash position), and anticipated U.S. market expansion.
• Employees: Continued expansion of operations and strategic initiatives may lead to stable or growing employment opportunities, particularly in medical cannabis and distribution.
• Customers: Continued focus on product development, research, and market expansion (e.g., Tilray Medical) suggests an ongoing commitment to serving customer needs with innovative products.
• Creditors: Reduction in total outstanding debt and a strong net cash position indicate improved creditworthiness and reduced risk.

Next Steps

• Leverage infrastructure, expertise, and know-how for Tilray Medical's global medical cannabis business.
• Rollout repeatable medical model and expand current research.
• Initiate new FDA trials and partnerships for product development in the U.S.
• Continue expanding operations and pursuing priorities to achieve sustainable profitability and enhance long-term shareholder value.
• Host a live audio webcast on January 8, 2026, at 4:30 p.m. Eastern Time to discuss results.

Key Dates

Recommendation

While Tilray Brands demonstrated strong top-line growth with record net revenue and a significant improvement in its balance sheet by achieving a net cash position, some core segments like beverages experienced declines. The reaffirmed Adjusted EBITDA guidance suggests stability, but the overall gross profit and margin saw a slight dip. The strategic positioning for U.S. cannabis rescheduling presents a substantial future opportunity, but its realization is contingent on regulatory changes. Given the mixed performance across segments and the forward-looking nature of the U.S. opportunity, a "hold" recommendation is appropriate for investors to observe the execution of strategic initiatives and the progression of regulatory changes.

Keywords

Cannabis, Tilray Brands, TLRY, Financial Results, Q2 Fiscal 2026, Net Revenue, Adjusted EBITDA, Medical Cannabis, Adult-Use Cannabis, Distribution, Tilray Pharma, Net Cash Position, SEC Filing, Earnings Report, Cannabis Rescheduling, Consumer Packaged Goods, Beverage Alcohol, Wellness